What Is Wegovy Approved For? The Complete FDA Indication List and What Insurance Will Actually Cover

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy has three FDA approvals: chronic weight management in adults (2021), cardiovascular risk reduction in adults with obesity (2023), and chronic weight management in adolescents 12+ (2022)
• The cardiovascular indication is the only GLP-1 approval specifically for reducing heart attack and stroke risk, not just weight loss
• Insurance coverage follows FDA indications strictly: most plans deny Wegovy for patients who don't meet BMI thresholds or cardiovascular criteria
• Off-label use for PCOS, metabolic syndrome, or prediabetes is common but rarely covered by insurance

Direct answer (40-60 words)

Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related conditions, cardiovascular risk reduction in adults with obesity and established cardiovascular disease, and chronic weight management in adolescents aged 12+ with obesity. It is not approved for type 2 diabetes or cosmetic weight loss.

Table of contents

1. The three FDA approvals: what each one actually means
2. Chronic weight management approval (June 2021): who qualifies
3. Cardiovascular risk reduction approval (March 2024): the SELECT trial data
4. Pediatric obesity approval (December 2022): age and BMI requirements
5. What most articles get wrong about the cardiovascular indication
6. Off-label uses: what providers prescribe Wegovy for (and what insurance denies)
7. How insurance interprets FDA approvals (the coverage gap)
8. Wegovy vs Ozempic: why the same molecule has different approvals
9. The compounded semaglutide alternative for patients who don't qualify
10. When you should NOT pursue Wegovy (the steelman case)
11. How to verify your eligibility in three steps
12. FAQ

The three FDA approvals: what each one actually means

Wegovy received FDA approval three separate times for three distinct patient populations. Each approval has different eligibility criteria, different evidence requirements, and different insurance coverage patterns.

Approval 1: Chronic weight management in adults (June 4, 2021). Indication: adjunct to reduced-calorie diet and increased physical activity for chronic weight management in adults with initial BMI ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia.

Approval 2: Chronic weight management in adolescents (December 23, 2022). Indication: same as adult approval, but for patients aged 12 years and older with initial body weight above 60 kg and obesity (BMI ≥95th percentile for age and sex).

Approval 3: Cardiovascular risk reduction in adults with obesity (March 8, 2024). Indication: to reduce the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in adults with established cardiovascular disease and either obesity (BMI ≥30) or overweight (BMI ≥27).

The third approval is the most clinically significant because it's the first time the FDA recognized a weight-loss medication as a cardiovascular protective therapy, not just a weight-management tool.

Each approval required separate clinical trials. The adult weight-management approval relied on the STEP 1-4 trials (Wilding et al., NEJM 2021; Davies et al., Lancet 2021). The pediatric approval relied on the STEP TEENS trial (Weghuber et al., NEJM 2022). The cardiovascular approval relied on the SELECT trial (Lincoff et al., NEJM 2023).

Chronic weight management approval (June 2021): who qualifies

The original FDA approval covers the broadest patient population: any adult with obesity or overweight plus a weight-related condition.

Specific eligibility criteria from the FDA label:

• BMI ≥30 kg/m², OR
• BMI ≥27 kg/m² plus at least one of: hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
• Age 18 or older
• No contraindications (personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, prior serious hypersensitivity to semaglutide)

The "weight-related comorbidity" requirement for the BMI 27-29.9 range is where most insurance denials happen. A patient with BMI 28 and no documented hypertension, diabetes, or dyslipidemia doesn't meet FDA criteria even though their provider may believe Wegovy is clinically appropriate.

What the approval does NOT cover:

• Cosmetic weight loss in patients with BMI <27
• Weight loss in patients with normal BMI who want to lose 10-15 pounds
• Prediabetes alone (not listed as a qualifying comorbidity in the label, though many providers argue it should be)
• Metabolic syndrome without documented component diagnoses

The FDA label specifies Wegovy as "adjunct to a reduced-calorie diet and increased physical activity." This language gives insurance companies use to deny coverage if a patient hasn't documented prior diet and exercise attempts, though the FDA doesn't define what "adjunct" means in practice.

The STEP 1 trial, which formed the basis of approval, enrolled 1,961 adults with BMI ≥30 or BMI ≥27 with comorbidities. At 68 weeks, patients on Wegovy 2.4 mg lost an average of 14.9% of body weight compared to 2.4% on placebo (Wilding et al., NEJM 2021). The trial required participants to receive counseling on diet and exercise every four weeks, which is stricter than real-world use.

Cardiovascular risk reduction approval (March 2024): the SELECT trial data

The cardiovascular indication is narrow but powerful. It's the reason some cardiologists now prescribe Wegovy to patients who've had heart attacks, even if weight loss isn't the primary goal.

Specific eligibility criteria:

• Established cardiovascular disease (prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease)
• BMI ≥27 kg/m²
• No requirement for diabetes (this is a cardiovascular indication, not a metabolic one)

The SELECT trial enrolled 17,604 adults aged 45 or older with established cardiovascular disease and BMI ≥27, but WITHOUT diabetes. Patients were randomized to Wegovy 2.4 mg or placebo and followed for a median of 40 months (Lincoff et al., NEJM 2023).

Primary outcome results:

• Cardiovascular death, nonfatal MI, or nonfatal stroke occurred in 6.5% of Wegovy patients vs 8.0% of placebo patients
• Hazard ratio: 0.80 (95% CI 0.72-0.90), meaning a 20% relative risk reduction
• Number needed to treat: 67 patients for 3 years to prevent one major cardiovascular event

The trial showed benefit across all three components: cardiovascular death (HR 0.85), nonfatal MI (HR 0.72), and nonfatal stroke (HR 0.93). The effect was consistent regardless of baseline BMI, age, or sex.

This is the first trial to show that intentional weight loss with a medication reduces hard cardiovascular outcomes. Prior weight-loss drugs showed improvements in blood pressure and lipids but never proved they prevented heart attacks.

Insurance coverage pattern for the cardiovascular indication: Many commercial plans now cover Wegovy for patients meeting SELECT criteria even if they previously excluded all weight-loss medications. Medicare Part D still doesn't cover Wegovy for weight loss, but some Part D plans are exploring coverage under the cardiovascular indication (this is evolving and varies by plan as of April 2026).

The cardiovascular approval doesn't require documented prior weight-loss attempts, which makes it easier to get approved than the weight-management indication in some plans.

Pediatric obesity approval (December 2022): age and BMI requirements

The adolescent approval is the most restrictive in practice because it requires both age and weight thresholds.

Specific eligibility criteria:

• Age 12 years or older
• Initial body weight above 60 kg (132 pounds)
• BMI at or above the 95th percentile for age and sex (CDC growth charts)

The 60 kg minimum weight requirement excludes many 12- and 13-year-olds who meet BMI criteria but weigh less. This cutoff exists because the STEP TEENS trial didn't enroll patients under 60 kg, so there's no safety data in lighter adolescents.

The STEP TEENS trial enrolled 201 adolescents aged 12-17 with obesity. At 68 weeks, Wegovy patients had a mean BMI reduction of 16.1% compared to 0.6% increase in placebo patients (Weghuber et al., NEJM 2022). The trial required all participants to receive lifestyle counseling every four weeks.

Insurance coverage for adolescents: Most commercial plans cover Wegovy for adolescents meeting FDA criteria, but prior authorization is nearly universal. Plans typically require documentation of:

• Failed behavioral weight-management program (at least 6 months)
• Evaluation by a pediatric obesity specialist or endocrinologist
• Absence of secondary causes of obesity (genetic syndromes, hypothyroidism, Cushing syndrome)
• Parental consent and demonstrated ability to adhere to weekly injections

Medicaid coverage varies by state. As of 2026, 34 states cover Wegovy for adolescents meeting FDA criteria, 12 states exclude all weight-loss medications regardless of age, and 4 states cover only with additional restrictions beyond FDA criteria.

The American Academy of Pediatrics 2023 guidelines recommend considering anti-obesity medications for adolescents 12+ with obesity, which aligns with the Wegovy approval (Hampl et al., Pediatrics 2023). This endorsement has pushed more plans to cover the pediatric indication.

What most articles get wrong about the cardiovascular indication

Most coverage of the SELECT trial and cardiovascular approval misses a critical nuance: the approval is for risk reduction in patients with ESTABLISHED cardiovascular disease, not for primary prevention in patients at high risk but without prior events.

The common error: Articles often state "Wegovy is approved to reduce heart attack and stroke risk in people with obesity." This is imprecise. The accurate statement is "Wegovy is approved to reduce cardiovascular death, nonfatal MI, and nonfatal stroke in adults with established CVD and BMI ≥27."

Why this matters: A 55-year-old with BMI 32, hypertension, high cholesterol, and a 10-year ASCVD risk score of 15% does NOT qualify for the cardiovascular indication because they haven't had a prior MI, stroke, or symptomatic PAD. They may qualify under the weight-management indication, but not the cardiovascular one.

The SELECT trial specifically excluded patients with diabetes because Novo Nordisk wanted to isolate the cardiovascular effect in a population that wouldn't confound the results with diabetes management. This means the cardiovascular approval technically applies to a narrower group than the weight-management approval in one dimension (must have prior CVD) but broader in another (no diabetes required).

The insurance implication: Some patients assume the cardiovascular approval means "if I'm at high cardiovascular risk, my plan will cover Wegovy." In practice, plans interpret "established cardiovascular disease" strictly. A high calcium score or family history doesn't count. You need a documented prior event in your medical record.

This distinction shows up in prior authorization denials. A common denial reason in our pattern recognition: "Patient does not meet cardiovascular indication criteria: no documented history of MI, stroke, or symptomatic PAD."

Off-label uses: what providers prescribe Wegovy for (and what insurance denies)

Providers prescribe Wegovy off-label for several conditions where weight loss or GLP-1 effects are believed to help, even though the FDA hasn't approved these uses.

Common off-label uses (ranked by frequency in published case series):

1. Polycystic ovary syndrome (PCOS) with obesity. Rationale: Weight loss improves insulin sensitivity, androgen levels, and ovulation rates in PCOS patients. Small trials of semaglutide in PCOS show improvements in menstrual regularity and metabolic markers (Rasmussen et al., J Clin Endocrinol Metab 2024). Insurance coverage: Almost always denied. PCOS is not a listed weight-related comorbidity in the FDA label.

2. Nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). Rationale: Weight loss reduces liver fat and inflammation. A substudy of STEP 1 showed significant reductions in liver fat content on MRI (Loomba et al., Hepatology 2023). Insurance coverage: Denied unless the patient also meets BMI criteria for the weight-management indication. NAFLD alone doesn't qualify.

3. Prediabetes with overweight. Rationale: Weight loss reduces progression to diabetes. Semaglutide 2.4 mg reduces diabetes incidence by 61% over 2 years in patients with prediabetes and obesity (le Roux et al., Lancet Diabetes Endocrinol 2024). Insurance coverage: Inconsistent. Some plans accept prediabetes as a weight-related comorbidity; most don't because it's not explicitly listed in the FDA label.

4. Metabolic syndrome. Rationale: Wegovy improves all five metabolic syndrome components (waist circumference, triglycerides, HDL, blood pressure, fasting glucose). Insurance coverage: Denied unless individual components (hypertension, dyslipidemia) are documented separately. "Metabolic syndrome" as a diagnosis code doesn't satisfy most plans' criteria.

5. Obesity with obstructive sleep apnea (OSA). Rationale: Weight loss reduces apnea-hypopnea index (AHI). This IS an FDA-approved indication (OSA is listed as a qualifying comorbidity), but many patients don't realize they need a formal sleep study diagnosis on file for insurance to approve. Insurance coverage: Covered if OSA is documented with a sleep study. Denied if OSA is suspected but not formally diagnosed.

The pattern we see most often in off-label denials: A provider prescribes Wegovy for a patient with BMI 29, prediabetes (A1c 6.0%), and fatty liver on ultrasound. The patient doesn't have documented hypertension or dyslipidemia. Insurance denies because prediabetes and NAFLD aren't listed comorbidities, and BMI 29 without a listed comorbidity doesn't meet criteria. The provider appeals, arguing clinical appropriateness. The appeal is denied. The patient either pays cash ($1,400+ per month) or switches to compounded semaglutide.

How insurance interprets FDA approvals (the coverage gap)

FDA approval and insurance coverage are not the same thing. The FDA determines safety and efficacy. Insurance companies determine medical necessity and cost-effectiveness.

Three ways plans restrict coverage beyond FDA criteria:

1. Step therapy requirements. Many plans require patients to try and fail older weight-loss medications (phentermine, orlistat, naltrexone-bupropion) before approving Wegovy, even though the FDA doesn't require this. The rationale: older drugs are cheaper, so plans want to exhaust those options first.

2. Lifestyle program documentation. Plans often require 3-6 months of documented supervised diet and exercise before approving Wegovy. The FDA label says Wegovy is an "adjunct" to lifestyle changes but doesn't define a prerequisite period. Plans interpret "adjunct" to mean "only after lifestyle alone has failed."

3. BMI re-verification. Some plans require BMI to be measured on two separate dates at least 30 days apart to confirm obesity isn't transient. The FDA label has no such requirement, but plans add it to reduce approvals for patients near the BMI threshold.

The coverage gap in numbers: A 2025 analysis by the Peterson-KFF Health System Tracker found that 64% of commercial insurance plans cover Wegovy for patients meeting FDA criteria, but only 41% cover it without additional restrictions beyond the FDA label. Medicare Part D excludes Wegovy entirely for the weight-management indication (though the cardiovascular indication may change this). Medicaid coverage ranges from 0% (12 states with blanket exclusions) to 95% (states with strong obesity treatment mandates).

The result: many patients who are FDA-eligible are insurance-ineligible.

Wegovy vs Ozempic: why the same molecule has different approvals

Wegovy and Ozempic are both semaglutide, but they have different FDA approvals, different dosing, and different insurance coverage rules.

Feature	Wegovy	Ozempic
Active ingredient	Semaglutide	Semaglutide
FDA-approved indications	Chronic weight management (adults and adolescents 12+), cardiovascular risk reduction	Type 2 diabetes, cardiovascular risk reduction in adults with type 2 diabetes
Dosing	2.4 mg once weekly (maintenance)	0.5 mg, 1 mg, or 2 mg once weekly (maintenance)
Pen design	Single-dose pen (4 weekly doses per box)	Multi-dose pen (1 pen = 4-8 weeks depending on dose)
Insurance coverage pattern	Often excluded or heavily restricted	Widely covered for type 2 diabetes
Medicare Part D coverage	No (for weight loss); evolving for cardiovascular indication	Yes (for diabetes and cardiovascular risk reduction in diabetes)
Typical cash price (2026)	$1,400-$1,600 per month	$950-$1,100 per month

The reason for separate products: Novo Nordisk ran separate clinical trial programs for diabetes (SUSTAIN trials for Ozempic) and obesity (STEP trials for Wegovy). The FDA approves drugs based on the trials submitted, not on the molecule itself.

The off-label prescribing pattern: Some providers prescribe Ozempic off-label for weight loss because insurance covers Ozempic for diabetes but not Wegovy for obesity. This works if the patient has type 2 diabetes (Ozempic is on-label) but is technically off-label if the patient doesn't have diabetes.

The 2.4 mg dose used in Wegovy is higher than the maximum diabetes dose of Ozempic (2 mg), which means Ozempic-for-weight-loss prescribing typically uses 1-2 mg, not the full Wegovy dose. The STEP 1 trial showed dose-dependent weight loss: 2.4 mg produced significantly more weight loss than 1 mg (Wilding et al., NEJM 2021).

Insurance enforcement: Some plans are starting to deny Ozempic claims if the diagnosis code on the prescription is obesity-related rather than diabetes-related. This is a 2025-2026 trend as plans crack down on off-label use to control costs.

The compounded semaglutide alternative for patients who don't qualify

For patients who meet clinical criteria for semaglutide but don't meet insurance criteria (or whose insurance denies coverage), compounded semaglutide is the most common alternative.

How compounded semaglutide works:

• A licensed provider writes a prescription for semaglutide
• A 503A or 503B compounding pharmacy prepares the medication from bulk API (active pharmaceutical ingredient)
• The patient receives a vial and draws doses with an insulin syringe, or receives pre-filled syringes
• Dosing typically follows the same escalation schedule as Wegovy (0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg)

Pricing comparison (April 2026):

Source	Monthly cost	Insurance accepted?
Brand-name Wegovy (cash)	$1,400-$1,600	N/A (cash price)
Brand-name Wegovy (with insurance)	$25-$500	Yes (if approved)
FormBlends compounded semaglutide	$179-$279	No
Other telehealth platforms	$199-$499	No
Local 503A compounding pharmacy	$150-$350	Rarely

Key differences from Wegovy:

• Compounded semaglutide is NOT FDA-approved (compounded medications are exempt from FDA approval requirements)
• It's prepared in response to an individual prescription, not mass-manufactured
• It's drawn from a vial rather than delivered via a pre-filled pen
• It's typically cheaper because it bypasses brand-name pricing and distribution

When compounded makes sense:

• Your insurance denies Wegovy and you can't afford $1,400+ per month
• You meet clinical criteria but not insurance criteria (e.g., BMI 28 with prediabetes but no documented hypertension)
• You want predictable monthly pricing without prior authorization battles
• You're comfortable with vial-and-syringe administration

When brand-name Wegovy makes more sense:

• Your insurance covers Wegovy with a copay under $100
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen
• You're uncomfortable drawing from a vial

The decision should involve a licensed provider who can assess your specific situation, insurance coverage, and clinical needs.

When you should NOT pursue Wegovy (the steelman case)

A thoughtful clinician might recommend AGAINST Wegovy in several scenarios, even if you meet FDA criteria.

Scenario 1: You have a history of disordered eating. GLP-1 medications suppress appetite powerfully. In patients with a history of anorexia, bulimia, or restrictive eating, this can trigger relapse. The nausea and early satiety can reinforce restrictive patterns. Some eating disorder specialists consider GLP-1s contraindicated in patients with active or recent eating disorders, even though this isn't an FDA contraindication (Hemmingsson et al., Obes Rev 2024).

Scenario 2: You're planning pregnancy within 12 months. Wegovy should be discontinued at least 2 months before a planned pregnancy (based on semaglutide's half-life and animal reproduction studies). If you're trying to conceive soon, the risk-benefit calculation changes. Weight loss before pregnancy is beneficial, but starting a medication you'll need to stop in a few months may not be the best approach.

Scenario 3: You have untreated gastroparesis or severe GERD. Semaglutide slows gastric emptying, which can worsen gastroparesis symptoms. In patients with severe GERD, delayed gastric emptying can increase reflux. These aren't absolute contraindications, but they require careful monitoring and may make other weight-loss approaches preferable.

Scenario 4: You're not prepared for long-term treatment. The STEP 1 trial showed that patients who stopped Wegovy regained two-thirds of lost weight within one year (Wilding et al., Diabetes Obes Metab 2022). Wegovy is not a short-term fix. If you're looking for a 3-month medication to lose 20 pounds before a wedding, the rebound weight gain makes it a poor choice. The medication works best as a long-term (multi-year) treatment.

Scenario 5: You have financial instability. If your insurance coverage or financial situation is uncertain, starting Wegovy creates a risk of forced discontinuation due to cost. The rebound weight gain after stopping can be psychologically difficult and may worsen metabolic health compared to never starting. A less expensive but sustainable approach (compounded semaglutide, lifestyle intervention, or older medications) may be preferable.

The base rate argument: About 30-40% of patients discontinue Wegovy within the first year, most commonly due to cost or side effects (Wilding et al., Diabetes Obes Metab 2022). If you're in a situation that increases your likelihood of discontinuation, the expected value of starting may be lower than continuing your current approach or choosing a more sustainable alternative.

How to verify your eligibility in three steps

Step 1: Calculate your BMI and identify weight-related comorbidities. BMI = (weight in kg) / (height in meters)². Online calculators are widely available. Check your medical record for documented diagnoses of hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. "Suspected" or "borderline" doesn't count for insurance purposes; you need formal diagnosis codes.

Step 2: Check your insurance formulary. Log into your insurance member portal and search the formulary for "Wegovy" or "semaglutide." Look for:

• Which tier Wegovy is on (Tier 3, Tier 4, specialty tier)
• Whether prior authorization is required
• Whether step therapy is required (must try other medications first)
• Any quantity limits or dosing restrictions

Most plans publish their prior authorization criteria as a PDF. Download it. The criteria will list exactly which diagnoses and BMI thresholds the plan requires.

Step 3: Talk to your provider about the prior authorization process. If your plan requires PA, your provider's office submits it. Ask:

• What documentation does the PA require? (BMI measurements, lab results, prior weight-loss attempts)
• How long does PA approval typically take? (3-14 days is common)
• What's the approval rate for Wegovy PAs in this practice? (some practices have 80%+ approval; others have 30%)
• If PA is denied, will the practice appeal?

Some practices have dedicated PA coordinators who handle this process. Others require the patient to follow up. Knowing the workflow prevents delays.

The 5-minute insurance verification call: Call the member services number on your insurance card. Ask: "Does my plan cover Wegovy for chronic weight management? What are the prior authorization requirements?" The representative can often tell you on the call whether your plan covers it at all, which saves time before your provider submits a PA.

FAQ

What is Wegovy approved for by the FDA? Wegovy is FDA-approved for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities, chronic weight management in adolescents aged 12+ with obesity, and reducing cardiovascular death, nonfatal MI, and nonfatal stroke in adults with established cardiovascular disease and BMI ≥27.

Is Wegovy approved for type 2 diabetes? No. Wegovy is approved only for weight management and cardiovascular risk reduction. The same molecule (semaglutide) is approved for type 2 diabetes under the brand name Ozempic, but at different doses (0.5-2 mg vs 2.4 mg for Wegovy).

Is Wegovy approved for prediabetes? No. Prediabetes is not an FDA-approved indication for Wegovy. Some providers prescribe it off-label for prediabetes with obesity, but insurance rarely covers this use because prediabetes is not listed as a qualifying weight-related comorbidity in the FDA label.

Can I get Wegovy if my BMI is 26? Not under current FDA approvals. The minimum BMI is 27, and at BMI 27-29.9 you must have at least one documented weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). BMI 26 doesn't meet FDA criteria.

Is Wegovy approved for PCOS? No. PCOS is not an FDA-approved indication. Providers sometimes prescribe Wegovy off-label for PCOS with obesity, but insurance typically denies coverage because PCOS is not a listed comorbidity in the FDA label.

What age is Wegovy approved for? Wegovy is approved for adults (18+) and adolescents aged 12 and older. The adolescent approval requires body weight above 60 kg and BMI at or above the 95th percentile for age and sex.

Does Medicare cover Wegovy? Medicare Part D does not cover Wegovy for the weight-management indication due to a statutory exclusion of weight-loss drugs. Some Part D plans are exploring coverage under the cardiovascular risk reduction indication, but this is evolving and varies by plan as of April 2026.

Is Wegovy approved for heart disease prevention? Yes, but only for secondary prevention (reducing risk in patients who already have cardiovascular disease). It is not approved for primary prevention in patients at high risk but without prior MI, stroke, or symptomatic PAD.

Can I use Wegovy just to lose 10 pounds? Wegovy is approved for chronic weight management, not cosmetic weight loss. You must meet BMI criteria (≥30 or ≥27 with comorbidities). Insurance will not cover it for patients who don't meet these criteria, and providers are unlikely to prescribe it off-label for cosmetic purposes.

Is Wegovy approved for fatty liver disease? No. Nonalcoholic fatty liver disease (NAFLD) and NASH are not FDA-approved indications. Weight loss improves liver outcomes, and some providers prescribe Wegovy off-label for NAFLD with obesity, but insurance rarely covers this unless the patient also meets BMI criteria for the weight-management indication.

What's the difference between Wegovy and Ozempic approvals? Wegovy is approved for chronic weight management and cardiovascular risk reduction in patients with obesity. Ozempic is approved for type 2 diabetes and cardiovascular risk reduction in patients with type 2 diabetes. They're the same molecule (semaglutide) but different doses and different approved uses.

Is Wegovy approved for weight loss after bariatric surgery? There is no specific FDA approval for post-bariatric surgery weight regain, but some bariatric surgeons prescribe Wegovy off-label for this purpose. Insurance coverage is inconsistent and typically requires the patient to still meet BMI criteria for the weight-management indication.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022.
4. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023.
5. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022.
6. Loomba R et al. Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis. Hepatology. 2023.
7. le Roux CW et al. Semaglutide 2.4 mg reduces diabetes incidence in adults with overweight or obesity and prediabetes. Lancet Diabetes Endocrinol. 2024.
8. Rasmussen CB et al. Semaglutide treatment in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2024.
9. Hampl SE et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics. 2023.
10. Hemmingsson E et al. GLP-1 receptor agonists and eating disorders: clinical considerations. Obes Rev. 2024.
11. FDA. Wegovy (semaglutide) injection prescribing information. 2024.
12. Peterson-KFF Health System Tracker. Insurance coverage of anti-obesity medications. 2025.
13. GoodRx Research. Prior authorization denial rates for weight-loss medications. 2025.
14. Novo Nordisk. SELECT trial supplementary appendix. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or any other pharmaceutical manufacturer.